CLEAR-AML
Showing 1 - 25 of 5,139
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States
Recruiting
- Refractory Acute Myeloid Leukemia
- +4 more
- CD371-YSNVZ-IL18 CAR T cells
-
Basking Ridge, New Jersey
- +6 more
Aug 29, 2023
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Bisantrene Dihydrochloride (high dose)
- +3 more
-
Newcastle, New South Wales, AustraliaCalvary Mater
Jul 14, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult Trial in Saint Louis (Decitabine, Bone marrow biopsy/aspirate,
Terminated
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia, Relapsed, Adult
- Decitabine
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
May 9, 2022
Hematologic Malignancies Trial in Assiut (CD56)
Recruiting
- Hematologic Malignancies
- CD56
-
Assiut, Egypt
- +1 more
Jul 20, 2022
Frequency and Risk Factors of Acute Myeloid Leukemia
Not yet recruiting
- Myeloid Leukemia
- Bone marrow aspirite for diagnosis
- (no location specified)
Mar 15, 2023
Acute Myeloid Leukemia Trial in Canada, Puerto Rico, United States (procedure, drug, behavioral)
Recruiting
- Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +13 more
-
Birmingham, Alabama
- +187 more
Apr 28, 2022
Acute Myeloid Leukemia Trial in Worldwide (Magrolimab, Venetoclax, Azacitidine)
Active, not recruiting
- Acute Myeloid Leukemia
- Magrolimab
- +6 more
-
Duarte, California
- +25 more
Feb 4, 2022
Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional
Completed
- Acute Myeloid Leukemia
- Conventional Cytogenetics Studies
- +2 more
-
Assiut, EgyptSouth Egypt Cancer Institute
Mar 7, 2022
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- +7 more
- Anti-CD123 ADC IMGN632
- +7 more
- (no location specified)
Dec 28, 2022
Acute Myeloid Leukemia (AML) Trial in Israel, Italy (Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine)
Completed
- Acute Myeloid Leukemia (AML)
- Busulphan plus Cyclophosphamide
- Busulphan plus Fludarabine
-
Tel Hashomer, Israel
- +25 more
Aug 19, 2021
MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)
Recruiting
- Myelodysplastic Syndromes
- +5 more
- description of MDS pzatient cohort
-
Brest, FranceChu Brest
Oct 27, 2022
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood Trial in Australia, Canada, United States
Completed
- Lymphoblastic Leukemia, Acute, Childhood
- Myelogenous Leukemia, Acute, Childhood
- Azacytidine
- +4 more
-
Los Angeles, California
- +22 more
May 14, 2021
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia
- KIT Mutation-Related Tumors
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Apr 7, 2023
Acute Myeloid Leukemia, Complex Karyotype Trial in Hong Kong (Decitabine)
Recruiting
- Acute Myeloid Leukemia
- Complex Karyotype
-
Hong Kong, Hong KongThe University of Hong Kong
Apr 26, 2021
AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))
Not yet recruiting
- AML, Adult
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
- (no location specified)
Nov 20, 2023
iN the Real Practice
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Vyxeos liposomal
-
Roma, ItalyPoliclinico Tor Vergata
Nov 16, 2023
AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- chidamide and azacitidine
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Sep 27, 2023
Hematological Malignancies Trial in United Kingdom, United States (Magrolimab, Azacitidine)
Active, not recruiting
- Hematological Malignancies
- Magrolimab
- Azacitidine
-
Duarte, California
- +26 more
Dec 7, 2022
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)
Not yet recruiting
- Acute Myeloid Leukemia
-
Houston, TexasMD Anderson Cancer Center
Oct 27, 2023
CAR, Acute Myeloid Leukemia Trial in Hefei (TAA05 cell injection)
Recruiting
- CAR
- Acute Myeloid Leukemia
- TAA05 cell injection
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Nov 3, 2021